BiotechTube

Tislelizumab + Pamiparib + Temozolomide + Sitravatinib + Ociperlimab + BAT1706 + Fruquintinib + BGB-15025 + Zanidatamab + BGB-A445 + Surzebiclimab + Lenvatinib + LBL-007

Phase 3Recruiting
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced Malignancies

Conditions

Advanced Malignancies

Trial Timeline

Dec 19, 2019 → Jul 1, 2026

NCT ID
NCT04164199

About Tislelizumab + Pamiparib + Temozolomide + Sitravatinib + Ociperlimab + BAT1706 + Fruquintinib + BGB-15025 + Zanidatamab + BGB-A445 + Surzebiclimab + Lenvatinib + LBL-007

Tislelizumab + Pamiparib + Temozolomide + Sitravatinib + Ociperlimab + BAT1706 + Fruquintinib + BGB-15025 + Zanidatamab + BGB-A445 + Surzebiclimab + Lenvatinib + LBL-007 is a phase 3 stage product being developed by BeOne Medicines for Advanced Malignancies. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04164199. Target conditions include Advanced Malignancies.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04164199Phase 3Recruiting

Competing Products

20 competing products in Advanced Malignancies

See all competitors
ProductCompanyStageHype Score
AK-105AkesoPhase 1
32
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
33
EXS21546BiotrialPhase 1/2
33
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
25
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
NBTXR3NanobiotixPhase 1/2
36
pegfilgrastim + LY2523355Eli LillyPhase 1
33
SON-1010Sonnet BioTherapeuticsPhase 1
28
SON-1010Sonnet BioTherapeuticsPhase 1/2
36
BT1718Bicycle TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
IMC-18F1Eli LillyPhase 1
33
Tadalafil + GemcitabineEli LillyPhase 1
33
OKI-179OnKure TherapeuticsPhase 1
25
OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + RibociclibOnKure TherapeuticsPhase 1
25
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
41
LY3434172Eli LillyPhase 1
33
ACR-2316Acrivon TherapeuticsPhase 1
25
BBP-398LianBioPhase 1
25

Other Products from BeOne Medicines

ZanubrutinibApproved
82
Zanidatamab + Tislelizumab + Trastuzumab + Capecitabine + Oxaliplatin + Cisplatin + 5-FluorouracilPhase 3
74
Zanubrutinib + Bendamustine + Rituximab + VenetoclaxPhase 3
74
Tislelizumab + Placebo + Cisplatin + Gemcitabine Hydrochloride + CarboplatinPhase 3
74
Sonrotoclax + Zanubrutinib + PlaceboPhase 3
74